Cytokinetics, Inc.

Neupharma, Inc.

Suzhou Neupharma Co., Ltd.

Smithkline Beecham Corporation

Other

Xiangping Qian

Bradley Paul Morgan

Yong-Liang Zhu

David John Morgans, Jr

Pu-Ping Lu

Gustave Bergnes

Alex R Muci

Luke W Ashcraft

Chihyuan Chuang

Scott E Collibee

Jeffrey Warrington

Zhe Yang

Fady Malik

Erica Anne Kraynack

Antonio Romero

Hong X Jiang

Bing Yao

Chihyuan (Grace) Chuang

Steven David Knight

Dashyant Dhanak

Nicholas D Adams

Cynthia A Parrish

Kevin J Duffy

Jianchao Wang

Duke Fitch

Rosanna Tedesco

Alexander Ramon Muci

Han-Jie Zhou

Whitney Walter Smith

Kathleen Ann Elias

Andrew I McDonald

Jeff Gardina

Adam Lewis Tomasi

Jennifer Kuo Chen Huang

Jeffrey T Finer

Bainian Feng

Wenyue Wang

Qing (Kevin) Lu

Todd Tochimoto

Jingge Liu

Yijun Cheng

Jinguo Cao

Yongliang Zhu

Yong-Iiang Zhu

David J Morgans

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

Substituted quinazolines for inhibiting kinase activity

Certain chemical entities, compositions, and methods

Chemical entities that are kinase inhibitors, their polymorphs, pharmaceutical compositions and methods of treatment of cancer are described herein.

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Amino-pyrimidine skeletal muscle modulators

Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.

Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Disclosed is a composition comprising an beautyberry total glycosides extract, and a method of preparation thereof, and the use of the composition thereof in preparing drugs for treating neurodegenerative diseases or skin diseases. The extract thereof is prepared from the leaves ofH.T. Chang orRolfe, and contains 18% to 45% verbascoside and 15% to 40% Arenarioside.

Beautyberry total glycosides extract and preparation method and use thereof

Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.

Growing community of inventors

Foster City, CA, United States of America

Xiangping Qian